You Are Not Fine: The Post-2020 Physiological Shift Standard Medicine Misses

The Numbers the Actuaries Saw First

In January 2022, the CEO of OneAmerica told reporters that working-age death rates were up by forty percent. He noted, for context, that a three sigma, two-hundred-year catastrophe would be a ten percent increase. Forty percent is not a catastrophe. It is a category that does not yet have a name.

The Society of Actuaries documented that ages 25 through 44 carried the highest relative excess in non-COVID mortality across the pandemic period. The UK Office for National Statistics reported that the rise in long-term sickness-related economic inactivity was ten times larger than demographic projections had predicted. The CDC reported that the disability rate among adults aged 18 to 44 jumped from 21 to 24 percent in a single year. The prevalence of multiple concurrent chronic conditions among the youngest adult cohort has risen by nearly a quarter over the past decade.

The actuaries noticed before the clinicians did. The insurance industry, which is paid to see population-level shifts that medicine is paid to miss, registered a signal that the standard workup still fails to detect.

This is the systemic liability nobody wants to underwrite. Pre-2020 reference ranges are being applied to post-2020 patients, and the gap between what the labs say and what the bodies are doing has become the central clinical problem of this decade.

The Chart on My Desk

She is 43. She walks into the office after being worked up by three other clinicians across two health systems, resulting in 18 months of labs. Everything is normal. CBC, normal. CMP, normal. TSH, normal. CRP, normal. ANA, normal. The cardiologist found no structural disease. The neurologist found no lesion. The endocrinologist found no deficit. She has been told, gently and not so gently, that she is fine.

She is not fine.

In 2019, she was a senior product manager who ran four times a week, slept seven hours, and could read a research paper start to finish without losing the thread. Now she describes cognitive fog that lifts and falls in unpredictable tides. She can complete a hard meeting, but the next morning, she cannot remember most of what she said. Her heart rate variability, which she has tracked on a wrist device since 2018, has collapsed from a steady 58 to a flat 22 and will not come back. She walks up two flights of stairs, and her legs feel like they belong to someone older, someone tired, someone in a body she does not recognize. Her sleep is the strangest part. She sleeps for eight hours and wakes as if she has slept for three.

She wants to know what is wrong with her. She wants to know whether she is imagining it. She wants to know whether she will ever be the person she was six years ago.

She is a composite. I want to be clear about that. The information is not from one patient, the wearable history is not from one patient, and the language used is not from one patient. But every detail is real. This is the chart I am now seeing two or three times a week.

You Are Not Imagining It: The Constellation

There is a constellation forming. I do not yet know what to call it, and I am suspicious of anyone who claims they do. But I can describe it.

• Dysautonomia signatures. Orthostatic intolerance and HRV collapse. The reason you cannot stand up without your heart racing or your vision graying.

• Mitochondrial dysfunction. Elevated lactate to pyruvate ratios, impaired fatty acid oxidation. The reason two flights of stairs now feels like a workout.

• Persistent low-grade inflammation. Invisible on standard CRP. The reason you feel like you are running a low fever that no thermometer registers.

• Immune dysregulation. T cell exhaustion and a rising signal of autoantibodies against receptors that regulate the very systems patients describe as broken. The reason the body now reacts to its own machinery.

• Accelerated biological aging. Visible on methylation panels. The reason a forty-three-year-old can have the epigenetic signature of a fifty-year-old.

• Loss of physiological range. The finding that troubles me most as a clinician.

Not a disease, in the traditional sense. Loss of range. The body’s ability to move from rest to exertion, from sympathetic to parasympathetic, from peak cortisol to nadir cortisol, from awake to deeply asleep, has narrowed. The dynamic system has flattened.

I am not claiming a single cause. The honest position, the only position the data supports, is that this is probably all of the above, weighted differently for each patient. Post-viral, and not just one virus. SARS-CoV-2 sits in a context that also includes EBV reactivation, HHV-6, and CMV, all of which surge under chronic immune load. Cumulative allostatic load from the 2020 through 2023 period. Environmental exposures that intersect with immune activation in ways we are only beginning to map. Social and psychological terrain that fractured along fault lines we had been pretending were stable. Each of these has measurable biological footprints. Each of these compounded.

Most of the writing in this space has already chosen its villain. The pattern I am describing does not have one villain. It has a stack. And the stack is the story.

How the Stack Was Built

The framework I keep returning to is allostatic load, and not because it is fashionable. It is the only model I know that can hold all these threads at once.

Bruce McEwen and Eliot Stellar introduced the term in 1993 to describe the cumulative physiological wear and tear that comes from repeated cycles of adaptation. The body does not pay one cost for stress and then return to baseline. It incurs a cost for activation, a cost for duration, and a cost for the inefficient turning on and off of the response. Over the years, those costs compound. McEwen later described what he called Type 2 allostatic overload, the version that arises when the chronic stressor is unrelenting, social, informational, and unable to trigger a physiological escape signal. He wrote that it can only be counteracted through learning and changes in the social structure. He was describing modernity. The pandemic simply turned the dial to its maximum setting.

What the 2020 to 2023 period delivered was a compound stressor stack. Forty percent of the global population experienced clinically significant sleep disruption during the first eighteen months. Hair cortisol rose by twenty-three percent in a UK community cohort over three months, with the largest jumps in those who already had a mental health history. Sedentary behavior in a two-hundred-thousand-person wearable cohort rose from thirty-eight percent to fifty-two percent and never returned to baseline. Social isolation and loneliness, measured independently, both elevated inflammation; together, they were superadditive. Layered on top of that was a respiratory virus that, in turn, causes autonomic, mitochondrial, and immune injury. Layered onto that were pharmaceutical interventions of varying types, economic disruption, mortality salience, and chronic vigilance. The stack did not arrive in sequence. It arrived simultaneously.

For some patients, the stack was survivable. For others, particularly those already running close to their allostatic ceiling, it tipped them into what appears to be a new operating set point. Peter Sterling’s framing helps here. The brain is fundamentally an organ of predictive regulation. It is constantly recalibrating its expectations of the environment and setting physiological parameters to match. When the environment is chronically dysphoric, the brain recalibrates upward. The new normal for cortisol, resting heart rate, and sympathetic tone becomes elevated because the brain now predicts the environment to be dangerous. This is optimal adaptation to a hostile signal field. It is also expensive.

Stress-induced allostasis makes the human body more mouse-like, accelerating energy expenditure to that of a shorter-lived, rapidly aging organism.

Picard, 2022

Martin Picard’s lab at Columbia has done the work of putting a price tag on it. The Energetic Model of Allostatic Load proposes that chronic stress triggers measurable hypermetabolism. Resting energy expenditure rises by 13 to 67 percent under sustained psychological stress. Higher resting energy expenditure is associated with a 25 to 53 percent increase in mortality over two to four decades. Picard’s group has described what they call mitochondrial allostatic load, the cellular consequence of being asked to do too much, too long, with too little recovery. The mitochondria, sensing chronic threat, shift from energy production into what Robert Naviaux at UCSD calls the Cell Danger Response, a conserved defense program in which cellular metabolism reorganizes around survival rather than function. Healing cannot be complete until the response resolves. When it persists, chronic illness results.

This is the molecular translation of cognitive fog. Cognitive fog is hypermetabolism in tissue that should be resting. It is the price of a brain predicting a threat it cannot escape.

Layered onto that mitochondrial picture is a collapse of vagal tone. The vagus nerve, the body’s primary bioelectric conduit for parasympathetic signaling and the central regulator of the cholinergic anti-inflammatory pathway that Kevin Tracey’s lab described two decades ago. The vagus is, in the most literal sense, the body’s inflammation thermostat. When it collapses, the thermostat is stuck in the on position. In one cohort, long COVID patients showed HRV abnormalities comparable to those of coronary artery disease patients.

And underneath the vagal collapse sits a disrupted microbiome. When the gut barrier is compromised, zonulin rises, tight junctions loosen, and bacterial endotoxin translocates into the systemic circulation, where it activates the very inflammatory pathways the vagus can no longer suppress. Inflammation in the gut weakens the signal that would normally calm it.

The reframe that matters most, the one I want clinicians to take seriously, is that we are not looking at a syndrome. We are looking at a population-level shift in the physiological baseline. Korean cohorts show that BMI, abdominal obesity, and fasting glucose all increased between 2019 and 2021 and did not return to baseline. Autonomic studies consistently show that parasympathetic suppression is a persistent rather than a transient feature. The labs are still being read against the old values.

Why Your Standard Workup Came Back Normal

The RECOVER cohort enrolled more than ten thousand participants across eighty-three US sites and ran them through twenty-five standard laboratory tests, the panels that every primary care physician orders when a patient walks in with what my composite patient walked in with. The investigators reviewed CBC, CMP, HbA1c, urinalysis, urine albumin-to-creatinine ratio, and platelet count. Among the most symptomatic patients, those scoring 12 or higher on the PASC (post-acute sequelae of SARS-CoV-2) index, there were no meaningful differences in mean laboratory values compared with those who scored 0. The largest study ever designed to ask whether standard panels can identify long COVID answered, no.

That is not because nothing is wrong. It is because the wrong questions are being asked. CBC and CMP cannot see allostatic load. A conventional thyroid panel, calibrated against reference ranges derived from a population that included undiagnosed subclinical disease, cannot detect functional hypothyroidism driven by elevated reverse T3. A single-time-point CRP cannot capture the rhythm of inflammation that suPAR captures, in which every COVID patient in one cohort exceeded the normal range, while CRP remained within it.

A static glucose value cannot see glycemic variability. A ten-second ECG cannot see HRV. A morning cortisol draw cannot capture the four-point diurnal pattern, where the actual signal of dynamic range loss resides.

Medicine has been reading static photographs of dynamic systems and calling the blur normal.

The signal lives in time series and in tissue compartments that the standard workup never visits. It lives in continuous HRV from wearable sensors. It lives in DunedinPACE methylation values, which can show a healthy-looking patient aging at two and a half biological years per chronological year. It is present in ceramide species such as C16:0 and C18:0, which surpass standard lipid panels for cardiovascular prediction and are not measured by any standard lipid panel. It lives in organic acids, lactate-to-pyruvate ratios, mitochondrial function panels, zonulin, GPCR autoantibodies, and a careful exposome assessment that takes seriously the environmental burden a patient walks in carrying. The information is in the body. The standard panel simply fails to interrogate it.

This is not an innocent oversight. It is a systemic failure to update the instruments. The framework was built for a population that no longer exists.

Four Protocols to Reclaim Your Range

The appetite for protocols in this space is enormous, and the evidence is uneven. I will not give you a prescription. I will give you four principles you can own.

Principle One: Restore Range Before Chasing Biomarkers

A flattened system cannot tell you anything useful about itself. The first move is to widen the dynamic window so the signal becomes legible.

Resonance-frequency breathing, at five to six breaths per minute, has more accumulated RCT evidence than almost any pharmacological intervention available for this presentation. A 2024 systematic review of 17 trials and 810 participants showed reductions in cortisol and salivary alpha-amylase, increases in baroreflex gain, and improvements in attention, executive function, sleep, depression, and anxiety. A long COVID-specific home protocol produced clinically meaningful improvement in cognitive fog, chest pain, asthenia, and dizziness within a month. The intervention costs nothing and can be taught in fifteen minutes. It belongs at the foundation of every post-2020 workup.

Principle Two: Nervous System Regulation Is Foundational, Not Adjunctive

This is where the contemplative traditions were operating far ahead of modern physiology. Buddhist and Christian contemplatives, Yogic pranayama practitioners, Sufi breath rituals, and Stoic attentional disciplines were not engaging in abstraction. They repeatedly accessed the same biological principle through different cultural languages. The breath is the fastest voluntary entry point to autonomic regulation, and the nervous system reorganizes downstream of it.

Slow diaphragmatic breathing at resonance frequency amplifies vagal afferent signaling through baroreflex entrainment, improves heart rate variability, stabilizes CO2 tolerance, and shifts cortical networks away from chronic threat prediction. Functional imaging studies now demonstrate what these traditions discovered empirically: breath alters limbic activation, attentional control networks, inflammatory tone, and interoceptive awareness in measurable ways. In dysautonomia, long COVID, traumatic stress, and chronic inflammatory syndromes; so restoring respiratory rhythm may be one of the highest leverage interventions available.

Transcutaneous auricular vagus nerve stimulation pilot trials, including the placebo-controlled COVIVA trial, are showing early signals in fatigue, autonomic regulation, and cognition that warrant serious attention. Neurostimulation, HRV biofeedback, transcranial stimulation, and other emerging neuromodulatory approaches may function less as symptom suppression and more as tools for restoring adaptive range within the nervous system itself. The goal is not relaxation. The goal is to regain flexibility, restore physiologic responsiveness, and restore coherent signaling across the system.

Principle Three: Mitochondrial Rehabilitation, With Caution

The PERCEIVE randomized trial of supervised aerobic training in long COVID showed a measurable improvement in VO2 peak after 6 months. But the same year saw a sobering correspondence from the Radboud Mitochondrial Medicine group warning that exercise prescription in patients with post-exertional malaise must be calibrated to oxidative capacity.

The harm caused by older graded exercise protocols stemmed from exceeding the anaerobic threshold. Zone 2, properly identified through metabolic testing or a validated proxy, is mechanistically distinct from that approach. For mitophagy support, urolithin A has the cleanest randomized trial data of any commercially available compound, with a four-month trial showing a twelve percent improvement in muscle strength and reductions in plasma acylcarnitines. NAD+ precursors raise NAD+ reliably. Whether that translates into functional outcomes in this population has not yet been established. Be honest about that with your patients.

Principle Four: Strategic Immune Modulation, In Selected Patients

Low-dose naltrexone has accumulating observational data and a pending randomized trial for post-COVID fatigue. Its mechanism, microglial modulation and endorphin-mediated immune recalibration, is among the most coherent on offer for the neuroinflammatory phenotype. And in a narrow subset, those with documented GPCR autoantibodies, complement activation, or microclot evidence, more aggressive intervention may be warranted.

My favorite, because I have seen it work in our clinic, is therapeutic (1.0 to 1.2 blood volume) plasma exchange (TPE). The combination of 70% plasma volume exchange, fresh, clean albumin, and, especially, IVIG given at the end has been the biggest needle mover I have seen.

The Map Has Not Caught Up to the Terrain

We are six years into a population-level experiment in cumulative stressor loading, and medicine is still largely using pre-2020 reference ranges and frameworks to evaluate post-2020 patients. That is not a knowledge gap. It is a liability.

The signal is in the data, in the wearables, in the actuarial tables, in the labs we are not running. The signal is on the chart on my desk. The composite patient who walked through the door this week is not an outlier. She is the population.

The contemplative traditions held, for thousands of years, that the body has a kind of intelligence that the conscious mind is too noisy to hear. They were not wrong. The body has been reporting, accurately and continuously, what the last six years have cost it. The instruments to listen now exist. The reference ranges to interpret what they say are being rebuilt slowly, by people willing to admit that the old map no longer matches the terrain.

The question is not whether something has shifted. The question is whether we are going to build clinical models that match the terrain we are actually in.

If you are a clinician seeing this, what is your pattern? If you are a patient living it, what got missed? The chart on my desk is a composite. The conversation I want is not.

Health is a verb.

Health(v).